Comparisons of pharmaceutical registration to reimbursement in the 30 European Economic area countries [Abstract]

Salek, Mir-saeed, Patel, Shriti and Pichler, F. 2012. Comparisons of pharmaceutical registration to reimbursement in the 30 European Economic area countries [Abstract]. International Journal of Clinical Pharmacy 34 (1) , p. 222. 10.1007/s11096-011-9602-2

Full text not available from this repository.

Abstract

The inequalities presented across Europe with respects to patients’ access to new medicines in part results from differences in processes and activities of Health Technology Assessment (HTA) and reimbursement processes that follow an approval of marketing authorisation. There is a dilemma between provision of innovative new medicines and ensuring that the pharmaceuticals chosen meet the needs of their healthcare system, thus providing quality and an affordable price. A greater understanding of the European Economic Area (EEA) healthcare systems and their processes leading to reimbursement decision-making is required in order to help understand why different outcomes occur and to identify where process improvement may influence such outcomes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Springer Verlag
ISSN:	2210-7703
Last Modified:	07 Feb 2022 11:01
URI:	https://orca.cardiff.ac.uk/id/eprint/32866

Citation Data

Actions (repository staff only)

Edit Item